MNMariangela Niglio

Mariangela Niglio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariangela Niglio has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and genetic diversity of Blastocystis sp. among autochthonous and immigrant patients in Italy

    by Marianna Marangi, Sonia Boughattas, Rosella De Nittis, Daniela Pisanelli, Valeria Delli Carri, Maria Rosaria Lipsi, Gianfranco La Bella, Gaetano Serviddio, Mariangela Niglio, Sergio Lo Caputo, et al.


  • Open Access

    Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19

    by Mariacristina Poliseno, Donato Lacedonia, Mariangela Niglio, Federica De Gregorio, Graziano Antonio Minafra, Terence Campanino, Giulio Giganti, Giulia Scioscia, Teresa Antonia Santantonio, Maria Pia Foschino Barbaro, et al.

    Baricitinib, a reversible Janus-associated kinase-inhibitor, is approved for treating COVID-19, combined with Dexamethasone and, eventually, with Remdesivir (RDV). This retrospective cohort study assesses the real-life advantages and limits of Baricitinib in the current pandemic scenario. Data of all patients consecutively hospitalized with moderate/severe COVID-19 between 1 October 2021 and 31 March 2022 were retrospectively collected and described according to the treatment received (Baricitinib, Baricitinib + RDV, none). We performed survival analyses to estimate the 21-day probability of Intensive Care Unit (ICU) admission, death, and composite. We built multivariate Cox regression models to identify ICU admission/death predictors among patients’ features. Of 111 subjects, 28 received Baricitinib, 21 received Baricitinib + RDV, and 62 could not be treated due to pre-existing conditions. Treated patients had a comparable risk of death (HR 0.50, 95% C.I. 0.20–1.26, p = 0.14) but remarkably lower risk of 21-day ICU admission (H.R., 0.10, 95% C.I., 0.01–0.86, p = 0.03), regardless of the type of treatment received. At multivariable analysis, older age was the only predictor of ICU admission/death (HR 1.14, 95% C.I. 1.03–1.26, p ≤ 0.01).Although effective, the high prevalence of elderly, co-morbid patients limits Baricitinib use in the current pandemic setting.